Clinical trial NCT01282814: Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Sprinkle Study
Official title: Randomized, 2-way Crossover, Bioequivalence Study of Venlafaxine Hydrochloride 150 mg Extended-Release Capsules and Effexor® XR 150 mg Extended-Release Capsules Administered as the Content of 1 x 150 mg Extended-Release Capsule Mixed With Applesauce in Healthy Subjects Under Fasting Conditions.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Bioequivalence
Healthy Subjects
Lead sponsor: Teva Pharmaceuticals USA
Sponsor class: INDUSTRY
First posted: 2011-01-25
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: The objective of this study was to compare the rate and extent of absorption of venlafaxine hydrochloride 150 mg capsules (test) versus Effexor® XR (reference) administered as the content of 1 x 150 mg extended-release capsule mixed with applesauce under fasting conditions.


Eligibility criteria: Inclusion Criteria:

* Members of the community at large.
* Subjects will be females and/or males, non-smokers, 18 years of age and older.
* Female subjects will be postmenopausal or surgically sterilized.

Exclusion Criteria:

* Clinically significant illness within 4 weeks of the administration of study medication.
* Clinically significant surgery within 4 weeks prior to the administration of the study medication.
* Any clinically significant abnormality found during medical screening.
* Any reason which, in the opinion of the medical sub-investigator, would prevent the subject from participating in the study.
* Abnormal laboratory tests judged clinically significant.
* Positive urine drug screen at screening.
* Positive testing for hepatitis B, hepatitis C, or HIV at screening.
* ECG abnormalities (clinically significant) or vital sign abnormalities at screening.
* Subjects with BMI greater than 30.0.
* History of significant alcohol abuse within 6 months of the screening visit or any indication of the regular use of more than 14 units of alcohol per week (1 unit is equal to 150 mL of wine, 360mL of beer, or 45 mL of alcohol 40%).
* History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana) within 3 months of the screening visit or hard drugs (such as cocaine, PCP, crack) within 1 year of the screening visit.
* History of allergic reactions to venlafaxine.
* History of allergic reactions to heparin.
* Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to administration of the study medication.
* Use of an investigational drug or participation in an investigational study within 30 days prior to administration of the study medication.
* History or presence of any clinically significant gastrointestinal pathology, unresolved gastrointestinal symptoms, liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of the drug.
* Any history or presence of clinically significant neurological, endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric, or metabolic disease.
* Use of prescription medication within 14 days prior to administration of study medication or over-the-counter products within 7 days prior to administration of study medication, except for topical products without systemic exposure.
* Positive alcohol breath test at screening.
* Subjects who have used tobacco in any form within the 90 days preceding study drug administration.
* Any food allergies, intolerance, restriction, or special diet that, in the opinion of the medical sub-investigator, contraindicates the subject's participation in this study.
* Subjects who have had a depot injection or implant of any drug 3 months prior to administration of study medication.
* Donation of plasma (500 mL) within 7 days. Donation or loss of whole blood prior to administration of the study medication as follows:

  * less than 300 mL of whole blood within 30 days or
  * 300 mL to 500 mL of whole blood within 45 days or
  * more than 500 mL of whole blood within 56 days.
* Subjects who have consumed food or beverages containing grapefruit within 7 days prior to administration of the study medication.
* Subjects with clinically significant presence or history of raised intra-ocular pressure or at the risk of acute narrow angle glaucoma.
* Subjects who have dentures or braces.
* Intolerance to venipunctures.
* Subjects with a clinically significant history of tuberculosis, epilepsy, asthma, diabetes, or psychosis will not be eligible for this study.
* Subjects who are unable to understand or unwilling to sign the Informed Consent Form.
* Subjects with the known presence of volume-depletion.
* Subjects predisposed to bleeding of the skin and mucous membrane (impaired platelet aggregation).
* Subjects with clinically significant history of seizures.
* Additional exclusion criteria for females only:

  * Breastfeeding subjects.
  * Positive urine pregnancy test screen at screening.

Primary outcomes:
measure: Cmax of Venlafaxine.
timeFrame: Blood samples collected over a 48 hour period.
measure: AUC0-t of Venlafaxine.
timeFrame: Blood samples collected over a 48 hour period.
measure: AUC0-inf of Venlafaxine.
timeFrame: Blood samples collected over a 48 hour period.
Secondary outcomes:
Other outcomes:
Locations:
city: Sainte-Foy
country: Canada
facility: Anapharm Inc.
state: Quebec
Study officials:
affiliation: Anapharm
name: Benoit Girard, M.D.
role: PRINCIPAL_INVESTIGATOR
References: